Navigation Links
GSK and Amicus Therapeutics Enter Exclusive Worldwide Agreement to Develop and Commercialize Amigal™ for Fabry Disease
Date:10/29/2010

orate Executive Team.   "Our focus now is to continue to advance Amigal for Fabry disease and it is our hope to deliver a first-in-class, oral medicine to the thousands of people worldwide living with this devastating rare disease."

John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics said, "The completion of this agreement with GSK is a transformational event for Amicus. It provides a strong validation of the potential for Amigal to become an important new treatment option for people living with Fabry disease and for our pharmacological chaperone technology broadly.  GSK has extremely impressive global clinical, regulatory and commercial expertise and a strong commitment to the development of treatments for rare diseases. We look forward to working in close partnership with them."  Crowley continued, "With this key strategic alliance with GSK and the added financial strength it provides, Amicus is now uniquely positioned to build shareholder value through our expertise in rare disease drug development."  

About Amigal™ (migalastat HCl) for the Treatment of Fabry DiseaseMigalastat HCl is an investigational treatment for Fabry disease and has the potential to be the first in a new class of oral, small molecule medicines called pharmacological chaperones.  It is designed to selectively bind to and stabilize the target enzyme alpha-galactosidase A (alpha-Gal A), which facilitates proper trafficking of the enzyme to the lysosomes, where it is needed to break down the target substrate globotriaosylceramide (GL-3).

Results from Phase 2 studies of migalastat HCl, which has orphan designation in both the US and EU, demonstrated that in subjects identified as responders to migalastat HCl treatment resulted in increased levels of alpha-Gal A, reduced levels of GL-3 as measured in renal interstitial capillary cells from kidney biopsies and in urine, and a potential positive impact on renal functio
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
11. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... BOSTON , Oct. 1, 2014   ... market-leading provider of Anesthesia Information Management Systems (AIMS), ... Systems, LLC , a wholly owned subsidiary of ... healthcare information systems and connectivity solutions.  ... http://photos.prnewswire.com/prnh/20140930/149407 This partnership ...
(Date:10/1/2014)... NeuroCall, Inc., ("NeuroCall") announced today that it ... Teleneurology services. Dr. Ricardo Garcia-Rivera , Founder and ... proud that our quality of service has been recognized ... lifesaving support and continuity of care to patients of ... the United States ." NeuroCall ...
(Date:10/1/2014)... , Oct. 1, 2014 Quantum ... scaling volume production of photoactive quantum dots for ... . While offering numerous advantages for solar power ... large quantities of quantum dots with which to ... kept them from commercial utilization and acceptance. The ...
Breaking Medicine Technology:Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 2Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 3NeuroCall Awarded Joint Commission Accreditation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 3
... 2011 Smith & Nephew Orthopaedics (NYSE: ... agreement with French biotechnology company Graftys. The deal gives ... calcium phosphate bone void filler in the U.S., and ... "We are committed to offering our surgeon customers innovative ...
... (OTC: HEWA) a leading VIPPS accredited retail mail-order pharmacy, ... ended March 31, 2011. In the ... increased $1,031,003 to $2,284,552, up 82% compared to the ... strength in its prescription business and the acquisition of ...
Cached Medicine Technology:Smith & Nephew Signs Distribution Agreement for Unique Injectable Bone Void Filler With Graftys 2Smith & Nephew Signs Distribution Agreement for Unique Injectable Bone Void Filler With Graftys 3HealthWarehouse.com Reports 82% Quarter-Over-Quarter Revenue Growth in the First Quarter 2011 2
(Date:10/1/2014)... people to keep their "eyes on the prize" may ... walking, staying focused on a specific target ahead can ... people walk there faster, psychology researchers have found. Their ... around the environment naturally, offers a new strategy to ... interested in exercise if physical activity seems daunting, which ...
(Date:10/1/2014)... 2014 Lifeinsurance-policy.com has released a ... life insurance prices for smokers. , Smoking will always ... Comparing quotes is the best method to find affordable ... customers who need coverage. , Whole life insurance ... the policy. Since the coverage is permanent, the initial ...
(Date:10/1/2014)... October 01, 2014 Join the more than ... Disorder Treatment Center’s first ever charity golf tournament to benefit ... with eating disorders who cannot afford treatment. The tournament will ... in Eureka, Mo. , The day-long event starts with ... reception and award dinner will begin at 5 p.m. and ...
(Date:10/1/2014)... Diet Doc understands that many of their clients ... their dieting attempts could be easily sabotaged by the temptation ... treatments into their programs as a way to control ... effective weight loss results, it also allows patients to stick ... their weight for the future. , Earlier versions of the ...
(Date:10/1/2014)... Bahir Dar, Ethiopia, at the occasion of the ... some 150 African and international leishmaniasis experts, results ... and efficacy monitoring plan, carried out by ... Uganda, and Ethiopia, were presented to key decision ... treatment of kala-azar with the combination of Sodium ...
Breaking Medicine News(10 mins):Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4Health News:Results of large-scale roll out of combination treatment for kala-azar in Eastern Africa 2
... Benefits, DALLAS, April 17 Affiliated Computer,Services, ... it has successfully,completed Phase I of the Government ... to attain the highest quality patient,care for the ... key technology partner, ACS has installed,state-of-the-art IT infrastructure ...
... identification of the dangerous disease , , WEDNESDAY, April 16 ... to accurately, rapidly, and non-invasively diagnose lung cancer with ... a new study suggests. , Oral cavity tissue damage ... a highly accurate indicator of similar lung tissue damage ...
... Calorie Information, ALEXANDRIA, Va., April 16 ... ruling upholding,a New York City regulation that requires ... on their menus and menu boards. This ruling ... filed by the New York State,Restaurant Association. The ...
... N.C., April 16 MedCath Corporation,(Nasdaq: MDTH ) ... its Board of Directors., Mr. Grossman brings a ... Board of Directors. He served as partner and health ... 2005,after 37 years with the firm. While with Pricewaterhouse ...
... trusted and global orthopaedics corporation and the developer of ... in the field, is pleased to announce that the ... nominated for the European Patent Offices Inventor of the ... still in school when he lost his foot in ...
... & H.B. 5285 Enables BCBSM to expand ... its Monopoly rather than Lower Rates, LANSING, Mich., ... the Blues to expand their unfair advantage into,a monopoly rather than ... & Competitive Insurance Market. The Coalition,represents a group of Michigan based, ...
Cached Medicine News:Health News:ACS Systems Improving Delivery of Healthcare in Malta 2Health News:ACS Systems Improving Delivery of Healthcare in Malta 3Health News:Mouth Swab May One Day Diagnose Lung Cancer 2Health News:Mouth Swab May One Day Diagnose Lung Cancer 3Health News:Statement of the American Diabetes Association Supporting Federal Court's Ruling on New York City Proposal 2Health News:Woodrin 'Woody' Grossman Appointed to MedCath's Board of Directors 2Health News:Inventor of Ossur's Flex-foot nominated for European Inventor of the Year 2008 2Health News:Coalition For A Fair & Competitive Insurance Market Says Senate Should Reject the Blues Attempt to Expand Their Unfair Advantage 2Health News:Coalition For A Fair & Competitive Insurance Market Says Senate Should Reject the Blues Attempt to Expand Their Unfair Advantage 3Health News:Coalition For A Fair & Competitive Insurance Market Says Senate Should Reject the Blues Attempt to Expand Their Unfair Advantage 4
Use these popular insert style bands to secure a bar code label inside the wristband pocket for maximum convenience and security....
... computer-generated Thermal Printing Wristbands and Tags ... thermal and thermal transfer printers. Direct ... a heat-sensitive thermal coating under the ... use heat to transfer highly durable ...
... Designed for use in ... Alzheimer units, where you may ... which is easy to apply ... The band's width is increased ...
... software produces bar coded patient identification ... sets on demand at patient care ... used for patient identification and in ... specimens, charges, etc. back to the ...
Medicine Products: